Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study.

Forest plot analysis showed that, when cytogenetic, genetic, and clinical criteria were analyzed separately, MR-cytogenetic alone (hazard ratio [HR], 5.76; 95% CI, 2.78-11.95; P < .001) and sM-AML alone (HR, 3.98; 95% CI, 1.10-14.46; P = .036) were significantly associated with inferior survival, whereas MR-molecular alone showed a trend toward worse outcome that did not reach statistical significance (HR, 1.97; 95% CI, 0.96-4.04; P = .063).

also in 53,322 other papers

However, in t-AML, survival differences across the ELN strata were less pronounced and did not reach statistical significance ( supplemental Figure 1 ).

also in 111,027 other papers